Skip to Main Content

Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity (SELECT)

Conditions

Diseases of the Cardiovascular System | Obesity & Weight Control

Phase IIIb

What is the purpose of this trial?

Brief Summary:

The researchers are doing the study to see if semaglutide may reduce the risk of having cardiovascular events in patients with overweight or obesity and with prior cardiovascular disease. The participant will either get semaglutide (active medicine) or placebo ("dummy" medicine). Which treatment the participants get is decided by chance. The participant's chance of getting semaglutide or placebo is the same. The participant will get the study medicine in a pen. The participants will need to use the pen to inject the study medicine in a skinfold once a week. The study will last for about 2.5 to 5 years. Participants will have up to 25 clinic visits with the study doctor

  • Trial with
    Novo Nordisk
  • Start Date
    08/05/2019
  • End Date
    09/27/2023
Trial Image

For more information about this study, contact:

Mari-Lynet Knight

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    08/08/2019
  • Study HIC
    #2000023836